Clinical Trial Update: Use Of GW274150 In The Prophylactic Treatment Of Migraine [Phase 2]

View source ↗

Summary

GlaxoSmithKline completed a Phase 2 trial evaluating GW274150 for migraine prophylaxis. The update notes the study status as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine Disorders

Drugs mentioned

• GW274150

Snippet

Sponsor: GlaxoSmithKline | Conditions: Migraine Disorders | Phase 2 | Status: COMPLETED